protein

Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His tag)

MBS2546580

0.05 mg

435 USD

Recombinant Protein

Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His tag)

[VEGFR2 / Flk-1 / CD309 / KDR]

[CD309, FLK1, VEGFR, VEGFR2, KDR]

[vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 2; vascular endothelial growth factor receptor 2; kinase insert domain receptor; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD_antigen: CD309]

[VEGFR2 / Flk-1 / CD309 / KDR]

[KDR; KDR; FLK1; CD309; VEGFR; VEGFR2; FLK1; VEGFR2; VEGFR-2; FLK-1; KDR]

Human Cells

1356

> 97 % as determined by SDS-PAGE

Lyophilized from sterile PBS, pH 7.4, 7.5% mannitol.

Store it under sterile conditions at -20°c to -80°C. It is recommended that the protein be aliquot and be used as soon as possible. Avoid repeated freeze- thaw cycles.

The secreted recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of rhVEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions.

SDS-PAGE

Source: Human. Predicted N Terminal: Ala 20

Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method. Bio-Activity: 1.- Using the Octet RED systerm, the affinity constant (Kd)of human VEGFR2-his bound to biotinylated human VEGF165 was 5.9 nM. 2.- Measured by its ability to inhibit the VEGF- dependetn profilerration of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 10-50 ug/mL in the presence of 10 ng/mL recombinant human VEGF165. Reconstitution: It is recommended that sterile water (200 uL) be added to the vial to prepare a stock solution of 0.25 mg/mL. Concentration is measured by UV-Vis. Stability: Samples are stable for up to twelve months from date of receipt at -70°C .

Background: VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression. Description: A DNA sequence encoding the extracellular domain of human VEGFR2 (NP_002244.1) (Met 1-Glu 764) was fused with a polyhistidine tag at the C-terminus.

11321597

NP_002244.1

NM_002253.2

P35968

Angiogenesis Pathway (198772); Cardiac Progenitor Differentiation Pathway (712094); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Endocytosis Pathway (102279); Endocytosis Pathway (102181); Focal Adhesion Pathway (198795); Focal Adhesion Pathway (83067); Focal Adhesion Pathway (478); HIF-2-alpha Transcription Factor Network Pathway (137956)

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

0.05 mg

435 USD

0.1 mg

635